Dup	dup	O	O	OTHERS	I
753	753	O	O	OTHERS	I
prevents	prevents	O	O	O	O
the	the	O	O	O	O
development	development	O	O	O	O
of	of	O	O	O	O
puromycin	puromycin	O	O	O	O
aminonucleoside-induced	aminonucleoside-induced	O	O	O	O
nephrosis	nephrosis	O	DISEASE	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
appearance	appearance	O	O	O	O
of	of	O	O	O	O
nephrotic	nephrotic	O	DISEASE	OTHERS	I
syndromes	syndromes	O	DISEASE	OTHERS	I
such	such	O	O	O	O
as	as	O	O	O	O
proteinuria	proteinuria	O	DISEASE	OTHERS	I
,	,	O	O	O	O
hypoalbuminemia	hypoalbuminemia	O	O	OTHERS	I
,	,	O	O	O	O
hypercholesterolemia	hypercholesterolemia	O	DISEASE	OTHERS	I
and	and	O	O	O	O
increase	increase	O	O	O	O
in	in	O	O	O	O
blood	blood	O	O	OTHERS	I
nitrogen	nitrogen	O	O	OTHERS	I
urea	urea	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
induced	induced	O	O	O	O
in	in	O	O	O	O
rats	rats	O	O	O	O
by	by	O	O	O	O
injection	injection	O	O	O	O
of	of	O	O	O	O
puromycin	puromycin	CHEMICALS	O	OTHERS	I
aminonucleoside	aminonucleoside	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
markedly	markedly	O	O	O	O
inhibited	inhibited	O	O	O	O
by	by	O	O	O	O
oral	oral	O	O	O	O
administration	administration	O	O	O	O
of	of	O	O	O	O
Dup	dup	O	O	OTHERS	I
753	753	O	O	OTHERS	I
(	(	O	O	O	O
losartan	losartan	CHEMICALS	O	OTHERS	I
)	)	O	O	O	O
,	,	O	O	O	O
a	a	O	O	O	O
novel	novel	O	O	O	O
angiotensin	angiotensin	CHEMICALS	O	OTHERS	I
II	ii	CHEMICALS	O	OTHERS	I
receptor	receptor	O	O	O	O
antagonist	antagonist	O	O	O	O
,	,	O	O	O	O
at	at	O	O	O	O
a	a	O	O	O	O
dose	dose	O	O	O	O
of	of	O	O	O	O
1	1	O	O	O	O
or	or	O	O	O	O
2	2	O	O	O	O
mg/kg	mg/kg	O	O	O	O
per	per	O	O	O	O
day	day	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
results	results	O	O	O	O
suggest	suggest	O	O	O	O
a	a	O	O	O	O
possible	possible	O	O	O	O
involvement	involvement	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
renin-angiotensin	renin-angiotensin	O	O	O	O
system	system	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
development	development	O	O	O	O
of	of	O	O	O	O
puromycin	puromycin	O	O	O	O
aminonucleoside-induced	aminonucleoside-induced	O	O	O	O
nephrosis	nephrosis	O	DISEASE	OTHERS	I
.	.	O	O	O	O

